Biomarkers of Alzheimer's Disease as predictors of neuropsychiatric symptoms in patients with Subjective Cognitive Decline and Mild Cognitive Impairment

• Grant number: 21/11729-8
• Support type: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): February 01, 2022
• Effective date (End): January 31, 2023
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal researcher: Marcio Luiz Figueredo Balthazar
• Grantee: Ana Luiza Gonçalves Rochetti
• Home Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated research grant: 18/15571-7 - Mapping the progression of subjective cognitive decline to mild cognitive impairment and Alzheimer´s disease dementia with multimodal biomarkers, AP.JP2

Abstract

Population ageing is a global trend and a risk factor for dementias. Therefore, this sindrome occurrence is increasing around the world and Alzheimer's Disease (AD) is the most prevalent one between them. Pathophysiologically, Alzheimer's Disease can be characterized by the presence of b-amyloid plaques on cerebral cortex and neurofibrillary tangles, biomarkers that can be measured by cerebrospinal fluid. Clinically, Alzheimer's Disease tipically presents cognitive impairment, as memory commitment, and loss of independence in daily activities. The Subjective Cognitive Decline (SCD) and Mild Cognitive Imparment (MCI) stages are potencial precedents of demential stages of Alzheimer's Disease. The presence of Neuropsychiatric Symptoms in AD continuum was observed, although its relation with AD pathophysiology is still not completely clear and literature evidences are contraditory, specially in prodromic stages of AD. Thereby, this research aims to verify if cerebrospinal fluid biomarkers are predictors of neuropsychiatryc symptoms in patients with SCD and MCI. (AU)